In June of 2016, the FDA issued a communication that emphasized the existing warning about acute kidney injury with the sodium glucose transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin, which are used for treatment of diabetes mellitus [13]. The gene discussed is SLC5A2; the disease is acute kidney injury.